LKB1 prevents ILC2 exhaustion to enhance antitumor immunity
Cell Reports · 2024
DOI: 10.1016/j.celrep.2023.113579 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Reports, 2024. Verfasst von Hongshen Niu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 2…. Hauptthemen laut MEDLINE: Protein Serine-Threonine Kinases, Lymphocytes, Immunity, Innate, AMP-Activated Protein Kinases. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 59 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.
Abstract (Originalsprache)
Group 2 innate lymphoid cells (ILC2s) play crucial roles in mediating allergic inflammation. Recent studies also indicate their involvement in regulating tumor immunity. The tumor suppressor liver kinase B1 (LKB1) inactivating mutations are associated with a variety of human cancers; however, the role of LKB1 in ILC2 function and ILC2-mediated tumor immunity remains unknown. Here, we show that ablation of LKB1 in ILC2s results in an exhausted-like phenotype, which promotes the development of lung melanoma metastasis. Mechanistically, LKB1 deficiency leads to a marked increase in the expression of programmed cell death protein-1 (PD-1) in ILC2s through the activation of the nuclear factor of activated T cell pathway. Blockade of PD-1 can restore the effector functions of LKB1-deficient ILC2s, leading to enhanced antitumor immune responses in vivo. Together, our results reveal that LKB1 acts to restrain the exhausted state of ILC2 to maintain immune homeostasis and antitumor immunity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Immune-Related Diseases at Shanghai Institute of Immunology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China; Department of Immunology and Microbiology, Key Laborator…
- Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200030, China.
- CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai 200031, China.
Förderung
- Ministry of Science and Technology of the People's Republic of China
- Science and Technology Commission of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Niu, H., Zhang, H., Wang, D., Zhao, L., Zhang, Y., Zhou, W., Zhang, J., Su, X., Sun, J., Su, B., Qiu, J., & Shen, L. (2024). LKB1 prevents ILC2 exhaustion to enhance antitumor immunity. Cell Reports. https://doi.org/10.1016/j.celrep.2023.113579
Vancouver
Niu H, Zhang H, Wang D, Zhao L, Zhang Y, Zhou W, et al. LKB1 prevents ILC2 exhaustion to enhance antitumor immunity. Cell Reports. 2024. doi:10.1016/j.celrep.2023.113579
BibTeX
@article{Niu2024,
author = {Niu, Hongshen and Zhang, Huasheng and Wang, Dongdi and Zhao, Linfeng and Zhang, Youqin and Zhou, Wenyong and Zhang, Jingjing and Su, Xiaohui and Sun, Jiping and Su, Bing and Qiu, Ju and Shen, Lei},
title = {LKB1 prevents ILC2 exhaustion to enhance antitumor immunity},
journal = {Cell Reports},
year = {2024},
doi = {10.1016/j.celrep.2023.113579}
}
EUVIMED